A self-contained kit and method for the on-demand synthesis of 2-deoxy-2-[.sup.18F]fluoro-D-sorbitol (.sup.18F-FDS) from commercially available 2-deoxy-2-[.sup.18F]fluoroglucose (.sup.18F-FDG) is disclosed.

The present invention relates to a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. In the formula (1), R.sup.1 to R.sup.3 are each independently a predetermined amino group or a predetermined amide group, or a group represented by the formula (2), and at least one of R.sup.1 to R.sup.3 is a group represented by the formula (2).

##STR00001##

Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

Embodiments of the present disclosure provide compositions and methods for performing positron emission tomography (PET) and, more particularly, to compositions and methods for the development and use of .sup.18F-based PET tracers for use in selected imaging techniques such as studies of myocardial physiology. In particular, as disclosed herein, at tracer levels, [.sup.18F]F—AraG has the ability to be used in a number of new PET methodologies including those designed for cardiac and/or mitochondrial activity imaging. The use of [.sup.18F]F—AraG as a PET tracer offers significant advantages over conventional .sup.18F labeled tracers in a number of distinct applications including observations of selected physiological phenomena such as myocardial perfusion, myocardial viability, and heart inflammation. Methods of the invention include those designed to use [.sup.18F]F—AraG to observe patient physiological responses to various therapeutic agents, as well as using [.sup.18F]F—AraG as a PET tracer in drug development studies.

Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

Disclosed are methods of forming an epimer or a dehydrated isomer of a pyranose monosaccharide or a pyranose saccharide residue in an oligosaccharide or a glycoside.

The present application provides compositions and methods for preparing and using “heavy” nucleotide derivatives of thymidine or uridine by replacing the oxygen atom attached to one or more of positions with non-radioactive oxygen-18 (.sup.18O), administering it to a subject to target a tumor including incorporation into tumor cell DNA, and then treating the tumor with proton beam therapy to transmutate the .sup.18O to .sup.18F, resulting in a break of the new fluorine-phosphorous bond. This chemical event destabilizes ribose-phosphate DNA back-bone and base pairing thus produce single- and double strand breaks, clusters lesions that can lead to irreparable DNA damage and enhanced tumor cell killing. The atomic, chemical, and physical aspects result in the use of lower radiation doses and significantly alter acute and late morbidity of radiotherapy. Heavy thymidine and heavy uridine derivatives labeled with .sup.18O have been made and tested.

Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.